Furthermore, miR-181c could exert chemoresistant functions and impede CML drug resistance, partly through targeting ST8SIA4 and its downstream PI3K/AKT pathway both in vitro and in vivo. Here, AKT1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.